SRI Biosciences works with academic, biopharmaceutical and biotechnology, foundation, and government clients and partners to bring new medicines and devices to market through basic research, pharmaceutical discovery, preclinical development and clinical translation. We have been a trusted partner to organizations worldwide for more than 50 years.
Today, combining the approaches of a nonprofit research institute, a biotech venture, and a contract research organization (CRO), SRI Biosciences integrates the R&D resources necessary to take drugs from Idea to IND® and beyond—from initial discoveries to first in human studies
Basic Biomedical Research
SRI Biosciences researchers solve important problems in prevention, diagnosis and treatment, targeting important unmet needs in healthcare and saving and improving lives worldwide. Our researchers strive to understand disease mechanisms, identify promising leads and translate preclinical candidates into clinical development. Core areas of therapeutic expertise include cancer, immunology and inflammation, infectious diseases and neuroscience. SRI also conducts bioscience R&D to produce new biomarkers, drug delivery technologies, medical devices, and systems biology tools.
Drug and Diagnostic Discovery
SRI Biosciences has discovered and developed marketed drugs such as Folotyn® (pralatrexate) and Targretin® (bexarotene) to treat various lymphomas; Ara-A® (Vidarabine) as an antiviral agent against Herpes simplex and Varicella zoster viruses; and Halfan® (halofantrine), to treat malaria. We have a full pipeline of new drugs and diagnostics in preclinical and clinical research.
Translational Development: Research and Development Services
In its capacity as a full-service CRO, SRI Biosciences has worked with clients and partners to conduct bioscience research and advance more than 100 drugs to human trials. SRI serves as a complete and reliable source for services ranging from idea to IND and beyond™, including synthesis, screening, efficacy, pharmacology, pharmacokinetics, safety, regulatory support, formulation, drug product manufacturing and early clinical trials.
SRI Biosciences’ facilities at SRI headquarters in the San Francisco Bay Area consist of approximately 250,000 ft2 of basic R&D laboratory space, and include Good Laboratory Practices (GLP)- and Current Good Manufacturing Practices (cGMP)-compliant facilities.
SRI Shenandoah Valley, a state-of-the-art 40,000-square-foot research facility in Harrisonburg, Virginia, focuses on health and biomedical research and drug discovery and development with the ultimate goal of bringing new therapies and diagnostics to market. The location also provides SRI Biosciences a convenient base for collaboration with private, government and academic institutions in Virginia and the greater Washington, D.C. area.
SRI’s Phase 1 Clinical Trial Facility occupies a purpose-built, approximately 9,400 square-foot expansion of the Michigan Life Science and Innovation Center in Plymouth, Michigan. The facility provides clients and partners with comprehensive early-stage human research capabilities for new medicines and medical devices.